Search
Indocyanine green acid form
go.drugbank.com/drugs/DB09374ApprovedInvestigationalEach vial of Indocyanine Green for Injection USP contains 25 mg of Indocyanine Green as a sterile lyophilized powder with no more than 5% sodium iodide. … Indocyanine Green for Injection USP has a pH of approximately 6.5 when reconstituted.
Categories: Compounds used in a research, industrial, or household settingGlyceryl monostearate
go.drugbank.com/drugs/DB11250ApprovedGlycerol monostearate, commonly known as GMS, is the glycerol ester of stearic acid . It is commonly used as an emulsifier in foods.
Mixtures: Mycellcare All in One SerumBalsalazide
go.drugbank.com/drugs/DB01014ApprovedBalsalazide works by deliverying mesalazine to the large intestine to act directly on ulcerative colitis. Mesalazine is also known as 5-aminosalicylic acid, or 5-ASA. … Balsalazide is an anti-inflammatory drug used in the treatment of Inflammatory Bowel Disease. It is sold under the name "Colazal" in the US and "Colazide" in the UK.
Categories: Anti-Inflammatory Agents, Non-Steroidal (Non-Selective), Analgesics, Non-NarcoticLiraglutide
go.drugbank.com/drugs/DB06655ApprovedInvestigational[A6932] Liraglutide was granted FDA approval on January 25, 2010.[L6070] … [A6932] Liraglutide is made by attaching a C-16 fatty acid (palmitic acid) with a glutamic acid spacer on the remaining lysine residue at position 26 of the peptide precursor.
Categories: Drugs Used in DiabetesSynonyms: Arg34Lys26-(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1[7-37], N²⁶-(N-Hexadecanoyl-L-gamma-glutamyl)-[34-L-arginine]glucagon-like peptide 1-(7-37)-peptideZanidatamab
go.drugbank.com/drugs/DB15471ApprovedInvestigationalZanidatamab is a bispecific antibody that binds two non-overlapping sites of HER2 (ERBB2). … [A264718] In November 2024, the FDA granted an accelerated approval for zanidatamab for use in previously treated unresectable or metastatic HER2-positive biliary tract cancers.[L51908,L51903]
Synonyms: SAPIENS ERBB2 (EPIDERMAL GROWTH FACTOR RECEPTOR 2, RECEPTOR TYROSINEPROTEIN KINASE ERBB-2, EGFR2, HER2, HER-2, P185C-ERBB2, NEU, CD340)), HUMANIZED MONOCLONAL ANTIBODY, BIPARATOPIC (TARGETING TWO DIFFERENT NON-OVERLAPPHydroxyzine
go.drugbank.com/drugs/DB00557ApprovedInvestigational[L9677] The active metabolite of hydroxyzine, [cetirizine], is also available as an active ingredient in allergic medications, and is responsible for much of its hydroxyzine's antihistaminic effect. … [A189753] Hydroxyzine is also used for generalized anxiety disorder, tension caused by psychoneurosis, and other conditions with manifestations of anxiety.[L9677]
Products: Nu-hydroxyzineSparsentan
go.drugbank.com/drugs/DB12548ApprovedInvestigationalaccelerated approval based on reduction of proteinuria. … [L45300] On April 24, 2024, sparsentan was granted conditional marketing authorization by the European Commission for the treatment of adults with primary IgAN.[L51559]
Categories: Agents Acting on the Renin-Angiotensin SystemDiroximel fumarate
go.drugbank.com/drugs/DB14783ApprovedInvestigational[A176474] It is the main cause of neurological disability not caused by trauma in the young adult population of both North America and Europe. … Relapsing-remitting forms of MS lead to neurological symptoms that resolve and recur periodically. More than 80% of patients suffering from this disease have relapsing-remitting MS.
Boceprevir
go.drugbank.com/drugs/DB08873ApprovedWithdrawnIn a joint recommendation published in 2016, the American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA) do not reccomend Boceprevir in combination … The substitutions of the enzyme's catalytic triad consisting of H58, D82, and S139 are also likely to alter the affinity of the drug for NS3/4A or the activity of the enzyme itself.
Categories: Antivirals for treatment of HCV infectionsSacituzumab govitecan
go.drugbank.com/drugs/DB12893ApprovedInvestigationalapproval for the treatment of mTNBC patients who have undergone two or more prior therapies. … [L13002, A193674] Sacituzumab govitecan was granted FDA approval on April 22nd, 2020 and is marketed under the brand name Trodelvy™ by Immunomedics, Inc.; it is currently indicated under accelerated